Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma

Overview

Journal Future Oncol

Specialty Oncology

Date 2017 Dec 9

PMID 29219612

Citations 13

Authors

Howard L Kaufman

Matthias Hunger

Meliessa Hennessy

Michael Schlichting

Murtuza Bharmal

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the association between tumor response and health-related quality of life (HRQoL) in patients with metastatic Merkel cell carcinoma treated with the anti-PD-L1 avelumab.

Materials & Methods: Phase II single-arm trial (NCT02155647) data of 88 patients were analyzed. Correlations between percentage reduction in tumor size and change from baseline in Functional Assessment of Cancer Therapy - General (FACT-G), FACT - Melanoma (FACT-M) and EuroQol-5 Dimension scores were calculated. HRQoL and utility by tumor response (per the Response Evaluation Criteria In Solid Tumors version 1.1) was estimated.

Results: Tumor shrinkage correlated positively with patients' change from baseline in the FACT-M total (0.364 [95% CI: 0.050-0.607]) and subscale scores. Differences in HRQoL and utility between nonprogressive disease and progressive disease were clinically relevant.

Conclusion: In patients with metastatic Merkel cell carcinoma, nonprogression during treatment with avelumab correlated with gains in HRQoL.

Citing Articles

Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.

Hoogland A, Brohl A, Small B, Michael L, Wuthrick E, Eroglu Z Cancer Med. 2024; 13(14):e7464.

PMID: 39021272 PMC: 11255021. DOI: 10.1002/cam4.7464.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Silk A, Barker C, Bhatia S, Bollin K, Chandra S, Eroglu Z J Immunother Cancer. 2022; 10(7).

PMID: 35902131 PMC: 9341183. DOI: 10.1136/jitc-2021-004434.

Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.

Gonzalez B, Eisel S, Bowles K, Hoogland A, James B, Small B J Natl Cancer Inst. 2021; 114(6):808-818.

PMID: 34508604 PMC: 9194633. DOI: 10.1093/jnci/djab171.

Bharmal M, Nolte S, Lebbe C, Mortier L, Brohl A, Fazio N Future Oncol. 2020; 16(27):2089-2099.

PMID: 32938212 PMC: 9437770. DOI: 10.2217/fon-2020-0426.

Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients.

Singh N, Alexander N, Lachance K, Lewis C, McEvoy A, Akaike G J Am Acad Dermatol. 2020; 84(2):330-339.

PMID: 32707254 PMC: 7854967. DOI: 10.1016/j.jaad.2020.07.065.